Inhibrx Biosciences (INBX) Accounts Payables (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Accounts Payables for 3 consecutive years, with $5.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accounts Payables fell 35.71% year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $5.9 million (down 35.71% YoY), while the FY2025 annual figure was $5.9 million, down 35.71% from the prior year.
• Accounts Payables declined to $5.9 million in Q4 2025 per INBX's latest filing, from $6.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $13.0 million in Q2 2024 and bottomed at $5.9 million in Q4 2025.
• Historically, Accounts Payables has averaged $9.4 million across 3 years, with a median of $9.1 million in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables dropped 15.6% — and 2025, when it tumbled 45.25%.
• Inhibrx Biosciences' Accounts Payables stood at $11.0 million in 2023, then decreased by 15.6% to $9.2 million in 2024, then slumped by 35.71% to $5.9 million in 2025.
• Business Quant data shows INBX's Accounts Payables at $5.9 million in Q4 2025, $6.8 million in Q3 2025, and $8.3 million in Q2 2025.